Similar to our results, He et al. found four metabolism-associated genes (GAS2, SLC17A4, NTM, and GC) is potential for predicting prognosis, and chemo-/immuno-therapy response in prostate cancer patients [61]. The gene discussed is GAS2; the disease is prostate carcinoma.